TY - JOUR
T1 - The effect of isoflurane on survival and myocardial infarction
T2 - A meta-analysis of randomized controlled studies
AU - Bignami, Elena
AU - Greco, Teresa
AU - Barile, Luigi
AU - Silvetti, Simona
AU - Nicolotti, Davide
AU - Fochi, Oliviero
AU - Cama, Elio
AU - Costagliola, Roberto
AU - Landoni, Giovanni
AU - Biondi-Zoccai, Giuseppe
AU - Zangrillo, Alberto
PY - 2013/2
Y1 - 2013/2
N2 - Objective: The aim of this meta-analysis was to investigate the cardioprotective properties of isoflurane versus any comparator in terms of the rate of myocardial infarction and all-cause mortality. Design: Pertinent studies were searched independently in Biomed, Central, PubMed, Embase, and the Cochrane Central Register of clinical trials. The primary endpoint was mortality at the longest follow-up available. Setting: A hospital. Participants: Randomized controlled trials. Intervention: A meta-analysis of 37 trials. Measurements and Main Results: The 37 included trials randomized 3,539 patients in cardiac (16 studies) and in noncardiac surgery (21 studies) with noninhalation comparators in 55% of trials. The overall analysis showed no difference in mortality between the isoflurane and control groups (16/1,602 [1.0%] v 23/1,937 [1.2%], odds ratios (OR) = 0.76 [0.39-1.47], p = 0.4 with 37 studies included) and no difference in the rate of myocardial infarction (3/1,312 [0.2%] v 1/1,532 [0.07%], OR = 2.03 [0.27-15.49], p = 0.5 with 30 studies included). Mortality was reduced in the isoflurane group when only studies with a low risk of bias were included in the analyses (0/540 [0%] v 5/703 [0.7%] in the control arm, OR = 0.13 [0.02-0.76], p = 0.02) with 4 cardiac and 6 noncardiac trials included and 5 noninhalation and 5 inhalation agents as the comparator. A trend was noted when a subanalysis was performed with propofol as a comparator (1/544 [0.2%] v 6/546 [1.1%], p = 0.05, with 16 studies included). Conclusions: Isoflurane reduced mortality in high-quality studies and showed a trend toward a reduction in mortality when it was compared with propofol. No differences in the rates of overall mortality and myocardial infarction were noted.
AB - Objective: The aim of this meta-analysis was to investigate the cardioprotective properties of isoflurane versus any comparator in terms of the rate of myocardial infarction and all-cause mortality. Design: Pertinent studies were searched independently in Biomed, Central, PubMed, Embase, and the Cochrane Central Register of clinical trials. The primary endpoint was mortality at the longest follow-up available. Setting: A hospital. Participants: Randomized controlled trials. Intervention: A meta-analysis of 37 trials. Measurements and Main Results: The 37 included trials randomized 3,539 patients in cardiac (16 studies) and in noncardiac surgery (21 studies) with noninhalation comparators in 55% of trials. The overall analysis showed no difference in mortality between the isoflurane and control groups (16/1,602 [1.0%] v 23/1,937 [1.2%], odds ratios (OR) = 0.76 [0.39-1.47], p = 0.4 with 37 studies included) and no difference in the rate of myocardial infarction (3/1,312 [0.2%] v 1/1,532 [0.07%], OR = 2.03 [0.27-15.49], p = 0.5 with 30 studies included). Mortality was reduced in the isoflurane group when only studies with a low risk of bias were included in the analyses (0/540 [0%] v 5/703 [0.7%] in the control arm, OR = 0.13 [0.02-0.76], p = 0.02) with 4 cardiac and 6 noncardiac trials included and 5 noninhalation and 5 inhalation agents as the comparator. A trend was noted when a subanalysis was performed with propofol as a comparator (1/544 [0.2%] v 6/546 [1.1%], p = 0.05, with 16 studies included). Conclusions: Isoflurane reduced mortality in high-quality studies and showed a trend toward a reduction in mortality when it was compared with propofol. No differences in the rates of overall mortality and myocardial infarction were noted.
KW - anesthesia
KW - intensive care
KW - isoflurane
KW - meta-analysis
KW - mortality
KW - myocardial infarction
KW - volatile
UR - http://www.scopus.com/inward/record.url?scp=84872135252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872135252&partnerID=8YFLogxK
U2 - 10.1053/j.jvca.2012.06.007
DO - 10.1053/j.jvca.2012.06.007
M3 - Article
C2 - 22819469
AN - SCOPUS:84872135252
VL - 27
SP - 50
EP - 58
JO - Journal of Cardiothoracic and Vascular Anesthesia
JF - Journal of Cardiothoracic and Vascular Anesthesia
SN - 1053-0770
IS - 1
ER -